查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗癌药物市场规模及预测 2021 - 2031、全球及地区份额、趋势及成长机会分析报告涵盖范围：依治疗类型、按适应症、按配销通路及按地域
市场调查报告书
商品编码
1804880

抗癌药物市场规模及预测 2021 - 2031、全球及地区份额、趋势及成长机会分析报告涵盖范围：依治疗类型、按适应症、按配销通路及按地域

Cancer Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, By Indications, By Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 277 Pages | 订单完成后即时交付

价格

预计到2031年，抗癌药物市场规模将从2024年的2,259.6亿美元增加至5,161.5亿美元。预计2025-2031年期间，该市场的复合年增长率将达到12.6%。推动市场成长的主要因素包括乳癌和肺癌发生率的上升，以及肿瘤学研究投资的激增，这些因素正在推动抗癌药物的推广应用。此外，在预测期内，个人化医疗的偏好可能会提振市场。然而，高昂的治疗费用是市场发展的限制因素之一。

日益加重的肺癌负担是驱动抗癌药物市场的重要因素，尤其是在 2023 年。肺癌仍然是全球最常见和最致命的癌症之一，约占所有癌症死亡人数的 25%。根据美国癌症协会的数据，2023 年，美国估计有 238,000 例新诊断出肺癌病例，约有 127,000 人死于该疾病。近一半的病例是在远处（转移性）阶段被诊断出来的，这种情况下五年存活率下降到 29%，这凸显了对更有效治疗方案的迫切需求。这项严峻的统计数据凸显了对有效治疗方案的迫切需求，并刺激了对创新疗法的需求。虽然吸烟仍然是约 85% 病例的主要危险因素，但从不吸烟者的肺癌比例正在上升，主要原因是空气污染，特别是在低于世卫组织空气品质标准的地区。非吸烟者中发病率的不断上升，凸显了对腺癌和其他与吸烟无直接关係的亚型的更广泛适用的治疗方法的未满足需求。

早期检测和精准医疗的进步对于应对这一日益严峻的挑战至关重要。开发标靶疗法、免疫疗法和联合疗法可以提高存活率和生活品质。 2023年，用于治疗EGFR突变型非小细胞肺癌（NSCLC）的新药Tagrisso（奥希替尼）的获批，以及正在进行的新型免疫检查点抑制剂临床试验，将持续重塑治疗模式。免疫疗法已显示出良好的疗效，Keytruda（派姆单抗）和Opdivo（纳武单抗）等药物透过利用人体免疫系统对抗癌症，显着改善了患者的预后。因此，乳癌发生率的上升推动了全球抗癌药物市场的成长。此外，民众对癌症意识的提高预计将对该市场的发展做出积极贡献。

比较公司分析根据产品组合（产品满意度、产品特性和可用性）、近期市场发展（併购、新产品发布和增强、投资和融资、奖励、协议、合作和伙伴关係、认可和扩展）以及地理位置对抗癌药物市场进行评估和分类，有助于更好地决策和了解竞争格局。该报告深入探讨了全球抗癌药物市场主要供应商近期的重要发展和创新。主要市场参与者包括百时美施贵宝公司、艾伯维公司、强生公司、罗氏有限公司、辉瑞公司、阿斯特捷利康公司、默克公司、诺华公司、安斯泰来製药公司和礼来公司。

根据治疗类型，抗癌药物市场分为化疗、标靶治疗、放射治疗、荷尔蒙治疗和其他治疗类型。标靶治疗在2024年占据了抗癌药物市场的最大份额。

根据适应症，市场分为血癌、肺癌、乳癌、大肠癌、摄护腺癌、胃癌、子宫颈癌、肝癌和肝内胆管癌、甲状腺癌和其他适应症。 2024 年，乳癌药物占据抗癌药物市场的最大份额，预计 2025 年至 2031 年期间的复合年增长率最高。乳癌是最常见的癌症之一，全球每年约有 230 万新病例被诊断出来。它是女性中的第一大癌症，并且仍然是全球癌症相关死亡的主要原因。然而，乳癌研究和治疗的重大进展大大提高了存活率，特别是在早期诊断中。标靶治疗、免疫疗法和个人化治疗方案的不断发展继续改变乳癌的治疗模式。

从配销通路来看，抗癌药物市场分为医院药局、零售药局和线上商店。 2024年，医院药房占据了抗癌药物市场的最大份额，预计在2025-2031年期间将实现最高的复合年增长率。

在抗癌药物市场中营运的公司采用各种有机和无机成长策略。有机成长策略主要包括产品发布和产品批准。市场上常见的无机成长策略包括收购、合作和伙伴关係。这些成长策略使市场参与者能够拓展业务，增强地域影响力，并促进整体市场成长。此外，收购和伙伴关係有助于巩固客户群并扩展产品组合。以下列出了抗癌药物市场主要参与者的一些重要进展。

2024 年，默克公司（在美国和加拿大以外称为 MSD）和私营临床阶段生物技术公司 LaNova Medicines Ltd.（LaNova）宣布，默克公司已获得独家全球许可，开发、生产和商业化 LM-299，这是 LaNova 的一种新型研究性 PD-1/VEGF 双特异性抗体。

2024年，中国国家药品监督管理局受理了安斯泰来和辉瑞的补充生物製品许可申请，​​将enfortumab vedotin与KEYTRUDA（帕博利珠单抗）联合用于晚期膀胱癌的一线治疗。

2023年，辉瑞宣布成功完成对Seagen公司的收购。 Seagen是一家全球生技公司，致力于发现、开发和商业化变革性抗癌药物。辉瑞以每股229美元现金的价格完成了对Seagen所有流通普通股的收购，企业总价值约430亿美元。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：
  • 假设和局限性

第四章：抗癌药物市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：抗癌药物市场－关键市场动态

  • 抗癌药物市场－关键市场动态
  • 市场驱动因素
    • 乳癌和肺癌负担日益加重
    • 肿瘤学研究投资激增
  • 市场限制
    • 治疗费用高昂
  • 市场机会
    • 政府和私人组织的支持增加
  • 未来趋势
    • 个人化医疗偏好
  • 驱动因素和限制因素的影响：

第六章：抗癌药物市场-全球市场分析

  • 2021-2031年抗癌药物市场收入
  • 抗癌药物市场预测分析

第七章：抗癌药物市场分析－依治疗类型

  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 荷尔蒙疗法
  • 其他治疗类型

第 8 章：抗癌药物市场分析 - 按适应症

  • 血癌
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 摄护腺癌
  • 胃癌
  • 子宫颈癌
  • 肝臟和肝内胆管癌
  • 甲状腺癌
  • 其他适应症

第九章：抗癌药物市场分析－按配销通路

  • 医院药房
  • 零售药局
  • 网上商店

第十章：抗癌药物市场-地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 亚太地区其他地区
  • 中东和非洲
    • 土耳其
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 12 章：产业格局

  • 概述
  • 市场倡议
  • 伙伴关係与合作
  • 其他发展

第十三章：公司简介

  • Bristol-Myers Squibb Co
  • AbbVie Inc
  • Astellas Pharma Inc
  • Eli Lilly and Co
  • Novartis AG
  • Merck KGaA
  • AstraZeneca
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson

第 14 章：附录

Product Code: TIPRE00040984

The cancer drugs market is projected to reach US$ 516.15 billion by 2031 from US$ 225.96 billion in 2024. The market is estimated to register a CAGR of 12.6% during 2025-2031. Major factors driving the market growth include a growing burden of breast and lung cancer, and surging investments in oncology research are propelling the adoption of cancer drugs. Further, the preference for personalized medicine will likely boost the market during the forecast period. However, the high cost of treatment is among the market deterrents.

The growing burden of lung cancer is a significant driver of the cancer drugs market, particularly in 2023. Lung cancer remains one of the most prevalent and deadly cancers globally, accounting for ~25% of all cancer deaths. According to the American Cancer Society, in 2023, an estimated 238,000 new cases of lung cancer were diagnosed in the US, and ~127,000 people died from the disease. Nearly half of the cases are diagnosed at distant (metastatic) stages, where survival drops to a 29% five-year survival, underscoring the critical demand for more effective therapeutic options. This grim statistic underscores the pressing need for effective treatment options and fuels the demand for innovative therapeutics. Although smoking remains the leading risk factor responsible for ~85% of cases, there is a rising share of lung cancer among never-smokers, driven primarily by air pollution, particularly in regions below WHO air quality standards. The increasing incidence among non-smokers accentuates the unmet need for more widely applicable treatments targeting adenocarcinoma and other subtypes not directly linked to tobacco exposure.

Advancements in early detection and precision medicine are pivotal in addressing this growing challenge. Developing targeted therapies, immunotherapies, and combination treatments improves survival rates and quality of life. In 2023, the approval of new drugs such as Tagrisso (osimertinib) for EGFR-mutant NSCLC and the ongoing clinical trials of novel immune checkpoint inhibitors continue to reshape the therapeutic landscape. Immunotherapy has shown promising results, with drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) significantly improving patient outcomes by harnessing the body's immune system to fight cancer. Therefore, the increasing incidence of breast cancer drives the global cancer drugs market growth. Additionally, the rising awareness of cancer among the population is expected to contribute positively to the development of this market.

The comparative company analysis evaluates and categorizes the Cancer Drugs market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global cancer drugs market. The key market players are Bristol-Myers Squibb Co.; AbbVie Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Merck KGaA; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Co.

Based on therapy types, the cancer drugs market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The targeted therapy segment held the largest cancer drugs market share in 2024.

By indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile ducts cancer, thyroid cancer, and other indications. The breast cancer segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR from 2025 to 2031. Breast cancer is one of the most prevalent forms of cancer, with an estimated 2.3 million new cases diagnosed globally each year. It is the leading cancer in women and remains a prime cause of cancer-related mortality worldwide. However, significant advancements in breast cancer research and treatment have dramatically improved survival rates, particularly in early-stage diagnoses. Ongoing developments in targeted therapies, immunotherapies, and personalized treatment regimens continue to transform the therapeutic landscape for breast cancer.

In terms of distribution channel, the cancer drugs market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR during 2025-2031.

Companies operating in the cancer drugs market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the cancer drugs market are listed below.

In 2024, Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that Merck had entered into an exclusive global license to develop, manufacture, and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

In 2024, China's National Medical Products Administration accepted Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer.

In 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for US$ 229 in cash per share, for a total enterprise value of approximately US$ 43 billion.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in Value Chain

5. Cancer Drugs Market - Key Market Dynamics

  • 5.1 Cancer Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Growing Burden of Breast and Lung Cancer
    • 5.2.2 Surging Investments in Oncology Research
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Treatment
  • 5.4 Market Opportunities
    • 5.4.1 Increased Support from Government and Private Organizations
  • 5.5 Future Trends
    • 5.5.1 Preference for Personalized Medicine
  • 5.6 Impact of Drivers and Restraints:

6. Cancer Drugs Market - Global Market Analysis

  • 6.1 Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Cancer Drugs Market Forecast Analysis

7. Cancer Drugs Market Analysis - by Therapy Types

  • 7.1 Chemotherapy
    • 7.1.1 Overview
    • 7.1.2 Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Targeted Therapy
    • 7.2.1 Overview
    • 7.2.2 Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Immunotherapy
    • 7.3.1 Overview
    • 7.3.2 Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Hormonal Therapy
    • 7.4.1 Overview
    • 7.4.2 Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Other Therapy Types
    • 7.5.1 Overview
    • 7.5.2 Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Cancer Drugs Market Analysis - by Indications

  • 8.1 Blood Cancer
    • 8.1.1 Overview
    • 8.1.2 Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Lung Cancer
    • 8.2.1 Overview
    • 8.2.2 Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Breast Cancer
    • 8.3.1 Overview
    • 8.3.2 Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Colorectal Cancer
    • 8.4.1 Overview
    • 8.4.2 Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Prostate Cancer
    • 8.5.1 Overview
    • 8.5.2 Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Stomach Cancer
    • 8.6.1 Overview
    • 8.6.2 Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Cervical Cancer
    • 8.7.1 Overview
    • 8.7.2 Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.8 Liver and Intrahepatic Bile Ducts Cancer
    • 8.8.1 Overview
    • 8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.9 Thyroid Cancer
    • 8.9.1 Overview
    • 8.9.2 Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.10 Other Indications
    • 8.10.1 Overview
    • 8.10.2 Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Cancer Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Online Stores
    • 9.3.1 Overview
    • 9.3.2 Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Cancer Drugs Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Cancer Drugs Market Overview
    • 10.2.2 North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.2.3 North America: Cancer Drugs Market Share - by Therapy Types
      • 10.2.3.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.2.4 North America: Cancer Drugs Market Share - by Indications
      • 10.2.4.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.2.5 North America: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.5.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.2.6 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.2.1 United States: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.2.2 United States: Cancer Drugs Market Share - by Indications
        • 10.2.6.2.3 United States: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.3 Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.3.1 Canada: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.3.2 Canada: Cancer Drugs Market Share - by Indications
        • 10.2.6.3.3 Canada: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.4 Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.4.1 Mexico: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.4.2 Mexico: Cancer Drugs Market Share - by Indications
        • 10.2.6.4.3 Mexico: Cancer Drugs Market Share - by Distribution Channel
  • 10.3 Europe
    • 10.3.1 Europe Cancer Drugs Market Overview
    • 10.3.2 Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.3.3 Europe: Cancer Drugs Market Share - by Therapy Types
      • 10.3.3.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.3.4 Europe: Cancer Drugs Market Share - by Indications
      • 10.3.4.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.3.5 Europe: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.5.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.3.6 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.2.1 Germany: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.2.2 Germany: Cancer Drugs Market Share - by Indications
        • 10.3.6.2.3 Germany: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.3 United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.3.1 United Kingdom: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.3.2 United Kingdom: Cancer Drugs Market Share - by Indications
        • 10.3.6.3.3 United Kingdom: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.4 France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.4.1 France: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.4.2 France: Cancer Drugs Market Share - by Indications
        • 10.3.6.4.3 France: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.5 Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.5.1 Italy: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.5.2 Italy: Cancer Drugs Market Share - by Indications
        • 10.3.6.5.3 Italy: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.6 Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.6.1 Spain: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.6.2 Spain: Cancer Drugs Market Share - by Indications
        • 10.3.6.6.3 Spain: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.7 Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.7.2 Rest of Europe: Cancer Drugs Market Share - by Indications
        • 10.3.6.7.3 Rest of Europe: Cancer Drugs Market Share - by Distribution Channel
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Cancer Drugs Market Overview
    • 10.4.2 Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.4.3 Asia Pacific: Cancer Drugs Market Share - by Therapy Types
      • 10.4.3.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.4.4 Asia Pacific: Cancer Drugs Market Share - by Indications
      • 10.4.4.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.4.5 Asia Pacific: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.5.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.4.6 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.2.1 China: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.2.2 China: Cancer Drugs Market Share - by Indications
        • 10.4.6.2.3 China: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.3 Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.3.1 Japan: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.3.2 Japan: Cancer Drugs Market Share - by Indications
        • 10.4.6.3.3 Japan: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.4 India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.4.1 India: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.4.2 India: Cancer Drugs Market Share - by Indications
        • 10.4.6.4.3 India: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.5 South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.5.1 South Korea: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.5.2 South Korea: Cancer Drugs Market Share - by Indications
        • 10.4.6.5.3 South Korea: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.6 Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.6.1 Australia: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.6.2 Australia: Cancer Drugs Market Share - by Indications
        • 10.4.6.6.3 Australia: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.7 Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.7.2 Rest of APAC: Cancer Drugs Market Share - by Indications
        • 10.4.6.7.3 Rest of APAC: Cancer Drugs Market Share - by Distribution Channel
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Cancer Drugs Market Overview
    • 10.5.2 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.5.3 Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
      • 10.5.3.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.5.4 Middle East and Africa: Cancer Drugs Market Share - by Indications
      • 10.5.4.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.5.5 Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.5.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.5.6 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.2.1 Turkey: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.2.2 Turkey: Cancer Drugs Market Share - by Indications
        • 10.5.6.2.3 Turkey: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.3 GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.3.1 GCC Countries: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.3.2 GCC Countries: Cancer Drugs Market Share - by Indications
        • 10.5.6.3.3 GCC Countries: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.4 South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.4.1 South Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.4.2 South Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.4.3 South Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.5 Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.5.2 Rest of Middle East and Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.5.3 Rest of Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
  • 10.6 South and Central America
    • 10.6.1 South and Central America Cancer Drugs Market Overview
    • 10.6.2 South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.6.3 South and Central America: Cancer Drugs Market Share - by Therapy Types
      • 10.6.3.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.6.4 South and Central America: Cancer Drugs Market Share - by Indications
      • 10.6.4.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.6.5 South and Central America: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.5.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.6.6 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.2.1 Brazil: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.2.2 Brazil: Cancer Drugs Market Share - by Indications
        • 10.6.6.2.3 Brazil: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.3 Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.3.1 Argentina: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.3.2 Argentina: Cancer Drugs Market Share - by Indications
        • 10.6.6.3.3 Argentina: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.4 Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.4.2 Rest of South and Central America: Cancer Drugs Market Share - by Indications
        • 10.6.6.4.3 Rest of South and Central America: Cancer Drugs Market Share - by Distribution Channel

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Market Initiative
  • 12.3 Partnerships and Collaborations
  • 12.4 Other Developments

13. Company Profiles

  • 13.1 Bristol-Myers Squibb Co
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AbbVie Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Astellas Pharma Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Eli Lilly and Co
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Novartis AG
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Merck KGaA
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AstraZeneca
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Pfizer Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Johnson & Johnson
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 List of Abbreviations

List Of Tables

  • Table 1. Cancer Drugs Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Table 4. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 5. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 6. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 8. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 9. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 10. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 11. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 12. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 13. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 14. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 15. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 16. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 17. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 18. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 19. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 20. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 21. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 22. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 23. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 24. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 25. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 26. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 27. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 28. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 29. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 30. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 31. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 32. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 33. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 34. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 35. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 36. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 37. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 38. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 39. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 40. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 41. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 42. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 43. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 44. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 45. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 46. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 47. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 48. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 49. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 50. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 51. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 52. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 54. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 55. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 56. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 57. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 58. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 59. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 60. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 61. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 62. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 63. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 64. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 65. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 66. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 67. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 68. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 69. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 70. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 71. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 72. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 73. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 74. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 75. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 76. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 77. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 78. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 79. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 80. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 81. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 82. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 83. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 84. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 85. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 86. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 87. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 88. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 89. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 91. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 92. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 93. List of Abbreviations

List Of Figures

  • Figure 1. Cancer Drugs Market Segmentation - Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cancer Drugs Market Share (%) - by Therapy Types (2024 and 2031)
  • Figure 6. Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Cancer Drugs Market Share (%) - by Indications (2024 and 2031)
  • Figure 12. Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Cancer Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 23. Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Cancer Drugs Market Regional Share, 2024 and 2031 (%)
  • Figure 27. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 28. North America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 29. North America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 30. North America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 31. North America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 32. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 34. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 36. Europe: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 37. Europe: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 38. Europe: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 39. Europe: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 40. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 41. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 42. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 43. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 44. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 47. Asia Pacific: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 48. Asia Pacific: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 49. Asia Pacific: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 50. Asia Pacific: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 51. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 52. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 54. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 55. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 56. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 57. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 58. Middle East and Africa: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 59. Middle East and Africa: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 60. Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 61. Middle East and Africa: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 62. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 66. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 67. South and Central America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 68. South and Central America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 69. South and Central America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 70. South and Central America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 71. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 72. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 73. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. Heat Map Analysis by Key Players
  • Figure 75. Company Positioning and Concentration